Advertisement


Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

2025 ASCO Annual Meeting

Advertisement

Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (Abstract 10503). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The study is important because for the longest time women's only option if they had an increased risk for gynecologic cancer because of hereditary predisposition like BRCA or Lynch syndrome or some of these other hereditary susceptibilities was they were recommended to and still are recommended to undergo risk-reducing hysterectomy. So it's a major quality of life issue. Right now, the only possible screening option for women with Lynch syndrome for uterine cancer is endometrial biopsy. The NCCN recommends that women can consider this. But unfortunately we know that they don't really work very well in terms of detecting uterine cancer as a pure screening test. And they're also very invasive and uncomfortable and cause a lot of pain. The idea behind the study is to try to develop a new way to screen for uterine cancer by using cell-free DNA, which we all know as more of a blood-based test, but in actuality, you can extract cell-free DNA from multiple body fluids. And so what the study has done is we looked at 16 patients with known uterine cancer that were going in for surgical operation, collected both a blood test and a cervical sample and extracted cell-free DNA from both body fluids. And then we compared tumor mutations, we sequenced them, compared tumor mutations in the actual tumor cancers to those that were found in the blood and those that were found in the cervical mucus sampling. And we found in what we're calling Pap ctDNA that over 90% of our mutations were detected in these early-stage cancers. In fact, it was 93% in FIGO grade 1 uterine cancer. In comparison, the blood test only detected about one-quarter of these. So we have a lot of work to do. This is a small feasibility study. We're in the process of expanding this more. I'm working on looking at other tumor types such as ovarian, which I've already been asked about, and hopefully we’ll be able to have an option for women for screening for these cancers for which they have not had effective screening.

Related Videos

Genomics/Genetics

Angela R. Bradbury, MD, on Genetic Testing Approach in Patients With Metastatic Cancers

Angela R. Bradbury, MD, of the University of Pennsylvania, presents findings from the eREACH trial—a randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers (Abstract 10502).  

Leukemia

William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004 

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy. 

 

Lung Cancer

Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial

Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009). 

Breast Cancer

Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4). 

Breast Cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer (Abstract 1013). They also discuss findings from the SERENA-6 and EMBER-3 trials, also presented at ASCO 2025, and what all this new data means for the sequencing of endocrine therapy in patients with breast cancer. 

Advertisement

Advertisement




Advertisement